ReviewEndocrine connections2022
Interactions between FGF23 and vitamin D.
Review in Endocrine connections, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Effects of sodium-glucose cotransporter 2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.BMC endocrine disorders · 2024Pooled it
- Review
- Review
- Impact of Gut Microbiota on Bone Metabolism-Present Concepts and Therapeutic Implications.International journal of molecular sciences · 2026Review
- Primary Hyperparathyroidism with Severe Vitamin D Deficiency in Chronic Kidney Disease.Internal medicine (Tokyo, Japan) · 2025Article
- The role of fat-soluble vitamins on bone metabolism and osteoporosis: a literature review.Annals of medicine · 2025Review
- Article
- Sex-dependent variation in bone adaptation: from degeneration to regeneration.Journal of orthopaedic translation · 2025Review
- Cross-talks between osteoporosis and gut microbiome.World journal of orthopedics · 2025Review
- Minerals and Human Health: From Deficiency to Toxicity.Nutrients · 2025Review
- Emerging concepts on the FGF23 regulation and activity.Molecular and cellular biochemistry · 2025Review
- The role of serum biomarkers in the decline of cognitive function in hemodialysis patients: a single-center retrospective study.Frontiers in medicine · 2025Article
- Specialty grand challenge: existing issues and emerging frontiers in renal endocrinology.Frontiers in endocrinology · 2025Article
- Analysis of factors influencing hemoglobin target achievement in maintenance hemodialysis patients in Wuhan, China.Frontiers in medicine · 2025Article
- Treatment-Resistant Hypophosphataemia After Ferric Carboxymaltose: Expanding the Spectrum of 6h Syndrome (Hypophosphataemia, Hyperphosphaturia, Hypovitaminosis D, Hypocalcaemia, Secondary Hyperparathyroidism, High Fibroblast Growth Factor-23).European journal of case reports in internal medicine · 2025Article
- Editorial: Endocrine imbalances of mineral ions and vitamins in chronic disease pathogenesis.Frontiers in endocrinology · 2025Article
- Fibroblast growth factor 23 and calcium-phosphate metabolism in relation to cardiovascular risk factors in patients with type 1 diabetes.Journal of diabetes · 2024Article
- Non-Classical Effects of FGF23: Molecular and Clinical Features.International journal of molecular sciences · 2024Review
- Editorial: Endocrine regulation of mineral ions and their relevance to metabolic diseases.Frontiers in endocrinology · 2024Article
- Relationships between blood bone metabolic biomarkers and anemia in patients with chronic kidney disease.Renal failure · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibroblast growth factor-23 (FGF23) controls the homeostasis of both phosphate and vitamin D. Bone-derived FGF23 can suppress the transcription of 1α-hydroxylase (1α(OH)ase) to reduce renal activation of vitamin D (1,25(OH)2D3). FGF23 can also activate the transcription of 24-hydroxylase to enhance the renal degradation process of vitamin D. There is a counter-regulation for FGF23 and vitamin D; 1,25(OH)2D3 induces the skeletal synthesis and the release of FGF23, while FGF23 can suppress the production of 1,25(OH)2D3 by inhibiting 1α(OH)ase synthesis. Genetically ablating FGF23 activities in mice resulted in higher levels of renal 1α(OH)ase, which is also reflected in an increased level of serum 1,25(OH)2D3, while genetically ablating 1α(OH)ase activities in mice reduced the serum levels of FGF23. Similar feedback control of FGF23 and vitamin D is also detected in various human diseases. Further studies are required to understand the subcellular molecular regulation of FGF23 and vitamin D in health and disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.